October 06, 2023
Thursday 26th October 2023 16:00 – 17:00 UK time
Location: Online via Microsoft Teams
To sign up to this event, please use the registration form to have access to the online invitation link.
The MTWC lecture series is primarily aimed at researchers and healthcare professionals, which means that elements of each lecture are likely to be very technical. However, interested members of the public are welcome to attend. Read on to find out more about what Dr Brintha Selvarajah will talk about during her MTWC lecture.
Fibrometabolism – an emerging therapeutic frontier in pulmonary fibrosis
Cellular metabolism describes the thousands of biochemical reactions that produce or use energy in living organisms. Alterations in these metabolic pathways have been shown to drive several human diseases, including more recently, pulmonary fibrosis.
In this talk, I will describe my research that delves into the emerging field of “fibrometabolism”, specifically highlighting the critical metabolic changes that promote fibrosis in the lung and the potential this new knowledge offers for the development of treatments in pulmonary fibrosis.
Dr Brintha Selvarajah Biography
Brinnie is a post-doctoral career development fellow at the Francis Crick Institute, London and an honorary respiratory consultant at University College London Hospital. She has a research and clinical interest in interstitial lung disease with a particular focus on idiopathic pulmonary fibrosis (IPF). Her research is focused on dissecting the mechanisms by which alterations in cellular metabolism can promote fibrosis.
Brinnie qualified in medicine from Oxford university and University College London, followed by the completion of her medical and respiratory training in London. She was awarded a Francis Crick PhD fellowship with Professor Rachel Chambers at UCL, followed by a NIHR lectureship and recently a post-doctoral clinical fellowship in Dr Mariia Yuneva’s Tumour Metabolism lab at the Francis Crick Institute. She also leads the ASPIRE study at UCL, which will utilise an integrated radiological, clinical, and multi-omics approach to characterise interstitial lung abnormalities (ILAs) to potentially identify predictive biomarkers of disease progression to pulmonary fibrosis and enable early diagnosis and intervention.
You may also be interested in:
Hope for All Research Appeal